Global Plasma Protein Products Market Size By Type (Albumin, Immunoglobulin), By Application (Hemophilia, Primary Immunodeficiency Disorder), By Region, And Segment Forecasts, 2023 to 2032

The Global Plasma Protein Products Market was valued at USD 29.1 billion in 2023 and is projected to reach USD 50.6 billion by 2031, expanding at a CAGR of 7.2% during the forecast period (2023–2031). Growth in the market is primarily driven by the rising prevalence of rare and chronic diseases, including primary immunodeficiency disorders, hemophilia, and other blood-related conditions. Increasing demand for immunoglobulin and albumin, expanding healthcare infrastructure, and technological advancements in plasma fractionation are further fueling market expansion.

Drivers:

Rising Prevalence of Chronic Diseases:

An increase in patients with chronic and life-threatening conditions—such as immune deficiencies and liver diseases—is significantly propelling the demand for plasma protein therapies globally.

Technological Advancements in Plasma Collection and Processing:

Innovations such as improved fractionation techniques, pathogen reduction technologies, and cold chain storage systems are enhancing production efficiency and product safety.

Growing Demand for Immunoglobulin Products:

Immunoglobulin is increasingly used to treat a broad spectrum of autoimmune, inflammatory, and infectious diseases, which is fueling global consumption.

Restraints:

High Cost of Plasma-Derived Therapies:

Plasma protein products are often expensive due to complex production processes, requiring extensive infrastructure and compliance with stringent regulations.

Limited Plasma Collection Capacity:

Despite rising demand, there is a global shortfall in plasma collection, especially in regions with restricted access to donation centers or regulatory challenges.

Opportunity:

Emerging Markets and Government Initiatives:

Expanding healthcare access and supportive government initiatives in countries like India, China, and Brazil are creating significant growth opportunities.

Personalized Medicine and Rare Disease Focus:

Rising investments in personalized medicine and orphan drug development are broadening the therapeutic applications of plasma-derived products.

Market by System Type Insights:

By product type, Immunoglobulin dominated the market in 2023, driven by its wide therapeutic scope. The segment continues to grow due to increasing approvals for new indications and rising awareness among clinicians. Albumin also accounted for a substantial share, particularly in surgical and trauma-related applications.

Market by End-use Insights:

Hospitals and Clinics were the largest end-users in 2023, accounting for over 50% of global revenue. This is attributed to the frequent use of plasma proteins in critical care and inpatient settings. The research institutes segment is projected to grow rapidly as clinical trials and R&D for new indications expand.

Market by Regional Insights:

North America led the global market in 2023, backed by an advanced healthcare system, large-scale plasma collection infrastructure, and the presence of leading industry players. Asia-Pacific is forecasted to register the fastest growth due to growing healthcare investments, favorable policies, and rising disease prevalence.

Competitive Scenario:

Key players in the global plasma protein products market include CSL Behring, Grifols, Takeda Pharmaceutical Company Limited, Octapharma, Kedrion Biopharma, China Biologic Products Holdings, LFB Group, Bio Products Laboratory Ltd (BPL), and ADMA Biologics. These companies focus on strategic acquisitions, global expansion, and advancing fractionation technologies to maintain their competitive edge.

Scope of Work – Global Plasma Protein Products Market

Key Market Developments:

2023: CSL Behring launched a new subcutaneous immunoglobulin therapy with extended shelf life and higher dosing flexibility.

2024: Grifols opened a new plasma collection center in Texas, boosting its annual plasma supply capacity.

2025: Takeda received FDA approval for its novel recombinant coagulation factor product, expanding its hemophilia treatment portfolio.

FAQs:

What is the current market size of the Global Plasma Protein Products Market?

The market was valued at USD 29.1 billion in 2023.

What is the major growth driver of the Global Plasma Protein Products Market?

Rising prevalence of chronic diseases and increasing demand for immunoglobulin are the primary growth drivers.

Which is the largest region during the forecast period in the Global Plasma Protein Products Market?

North America is the largest regional market.

Which segment accounted for the largest market share in Global Plasma Protein Products Market?

The Immunoglobulin segment accounted for the largest share in 2023.

Who are the key market players in the Global Plasma Protein Products Market?

Major players include CSL Behring, Grifols, Takeda, Octapharma, Kedrion, and China Biologic Products.